Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
65.18
+0.40 (0.62%)
At close: Apr 2, 2026, 4:00 PM EDT
64.00
-1.18 (-1.81%)
After-hours: Apr 2, 2026, 4:25 PM EDT
Disc Medicine Employees
Disc Medicine had 155 employees as of December 31, 2025. The number of employees increased by 71 or 84.52% compared to the previous year.
Employees
155
Change (1Y)
71
Growth (1Y)
84.52%
Revenue / Employee
n/a
Profits / Employee
-$1,368,929
Market Cap
2.49B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 155 | 71 | 84.52% |
| Dec 31, 2024 | 84 | 10 | 13.51% |
| Dec 31, 2023 | 74 | 28 | 60.87% |
| Dec 31, 2022 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Sarepta Therapeutics | 835 |
| Adaptive Biotechnologies | 624 |
| Ascentage Pharma Group International | 605 |
| Arcus Biosciences | 601 |
| Beam Therapeutics | 511 |
| Day One Biopharmaceuticals | 178 |
| Immunome | 177 |
IRON News
- 7 days ago - Disc Medicine, Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 7 days ago - Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - GlobeNewsWire
- 16 days ago - IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 5 weeks ago - Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Disc Medicine, Inc. (IRON) Discusses FDA Complete Response Letter and Path Forward for Bitopertin Regulatory Approval Transcript - Seeking Alpha
- 6 weeks ago - Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route - Reuters
- 7 weeks ago - US FDA declines to approve Disc Medicine's rare disease drug - Reuters
- 7 weeks ago - Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP - GlobeNewsWire